IVISense™ Folate Receptor 680 fluorescence imaging probe (FolateRSense™) is highly specific and sensitive in its detection of Folate Receptor alpha (FRa).
Used with in vivo imaging systems such as PerkinElmer's industry leading IVIS® platform, this targeted probe enables the non-invasive visualization and quantification of FR expression in highly metabolic cells such as tumor cells.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Folate receptors are a family of cell surface receptors that bind the essential vitamin folic acid (folate, vitamin B9). These receptors are upregulated in highly metabolic cells and over-expression of FRA protein is associated with tumor growth, as uptake of folic acid is a necessary part of tumor metabolism.
Folate is essential for cellular metabolism and DNA synthesis, methylation, and repair. High metabolic cells such as proliferating cancer cells have increased demand for folate to maintain their accelerated DNA synthesis; thus overexpression of folate receptors (FRs) is a recognized biomarker of many tumors, though tumors can differ in their dependence on folate metabolism.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||IVISense|
|Quantity in a Package Amount||1.0 Units|
|Therapeutic Area||Inflammation, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.
Learn about several important best practices, from proper probe selection to study design to imaging technique tips and tricks needed to generate meaningful biological information from your in vivo fluorescence imaging studies.
Overexpression of Folate Receptor (FR) protein is associated with tumor growth, and uptake of folic acid is a necessary part of tumor metabolism. The FolateRSense imaging agent is highly specific and sensitive in its detection of FR and can be used to closely monitor and quantitate tumor growth and metabolism.
Folic acid (vitamin B9) is an essential nutrient required by eukaryotic cells for survival that is acquired and internalized via folate receptors (FR) on the cell surface. In particular, it is the highly metabolic cells that upregulate FR, and many different human tumor cells, including ovarian, breast, cervical, renal, colorectal and nasopharyngeal cancer cells show significant upregulation as compared to normal tissues. As such, folic acid has been successfully exploited as a cancer specific targeting moiety for the efficient delivery of chemotherapeutic agents, drug carriers, photosensitizers and diagnostic reporters. Critical to the success of such agents is the determination of the level of FR expression for a given tumor, since weak FR-expressing cancers will not respond well to folate-targeted therapies. There is therefore a need for specific and quantitative imaging agents
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.